Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Aquestive Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-106.49 Mil. Aquestive Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $57.42 Mil.
Therefore, Aquestive Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -1.86.
The historical rank and industry rank for Aquestive Therapeutics's Equity-to-Asset or its related term are showing as below:
AQST'
s Equity-to-Asset Range Over the Past 10 Years
Min: -2.08 Med: -0.69 Max: 0.12
Current: -1.86
During the past 8 years, the highest Equity to Asset Ratio of Aquestive Therapeutics was 0.12. The lowest was -2.08. And the median was -0.69.
AQST's Equity-to-Asset is ranked worse than 95.58% of 1087
companies
in the Drug Manufacturers industry
Industry Median: 0.59
vs AQST: -1.86
Aquestive Therapeutics Equity-to-Asset Historical Data
The historical data trend for Aquestive Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aquestive Therapeutics's Equity-to-Asset
For the Drug Manufacturers - Specialty & Generic subindustry, Aquestive Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aquestive Therapeutics's Equity-to-Asset Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aquestive Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Aquestive Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Aquestive Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Aquestive Therapeutics Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Aquestive Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Aquestive Therapeutics (Aquestive Therapeutics) Business Description
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AQST has been successfully added to your 